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ABSTRACT 
Introduction: 
Of the volatile anaesthetic agents, desflurane causes the greatest degree of potentiation of the 
neuromuscular blocking drugs (NMB).  The purpose of this study was to determine whether 
desflurane prolongs the effects of 3xED95 doses of rocuronium and cisatracurium to the same 
degree.  The two NMB represent potent and less potent classes respectively. 
 
Methods: 
Informed, written consent was obtained from 63 adult patients scheduled for routine surgery.  
They were randomly allocated to one of four groups to receive either desflurane-sufentanil 
(end-tidal partial pressure 4.0 kPa) or propofol-sufentanil anaesthesia and either rocuronium 
(0.9mg/kg) or cisatracurium (0.15mg/kg).  All patients received a target-controlled sufentanil 
infusion (0.5 ng/ml).  Neuromuscular blockade was recorded using accelerometry (TOF-
GUARD®, Organon) while patients recovered spontaneously to a Train-of-Four ratio of 0.9 
(TOFR0.9).  Data were analysed using one- and two-way analysis of variance.  The main 
effects were the types of anaesthetic and NMB on indices of recovery. 
 
Results: 
Compared with propofol-sufentanil anaesthesia, mean times to recovery to T125% and 
TOFR0.9, were prolonged by desflurane-sufentanil (p<0.01).  There were no interactions.  
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Mean prolongation of time to TOFR0.9 was 41 min (SD 36) for cisatracurium and 26.6 min 
(SD 39) for rocuronium. 
 
Discussion: 
Whereas previous studies did not reveal prolongation of the duration of action of rocuronium 
by desflurane, we demonstrated a statistically significant prolongation of the spontaneous 
recovery times of both rocuronium and cisatracurium by desflurane.  From the data we could 
not conclude that there was a difference between the two NMB.  A power study revealed that 
in order to detect a difference between times to recovery to TOF0.9, a sample size of 101 
subjects per group would be required. 
 
Conclusion:  
Desflurane prolongs the mean time to spontaneous recovery from neuromuscular blockade 
after 3xED95 doses of both cisatracurium (a potent NMB) and rocuronium (a less potent 
NMB).  There was wide inter-individual variation in times to spontaneous recovery. Any 
difference in the mean prolongations between the different types of NMB is unlikely to be of 
clinical importance. 
 
Keywords 
Neuromuscular non-depolarizing agents, desflurane, rocuronium, cisatracurium, drug 
interactions, neuromuscular monitoring, train–of-four monitoring 
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OPSOMMING 
Inleiding 
Van al die vlugtige narkosemiddels veroorsaak desfluraan die grootste mate van potensiasie 
van die neuromuskulêre blokkeermiddels.  Die doel van hierdie studie was om vas te stel of 
desfluraan wel die effek van driedubbel die ED95 dosis van rokuronium en cisatrakurium tot 
dieselfde mate sal verleng. 
 
Metodiek 
Geskrewe ingeligte toestemming is verkry van 63 pasiënte wat voorgedoen het vir roetiene 
chirurgiese prosedures.  Pasiënte is lukraak in een van vier groepe ingedeel om of desfluraan-
sufentaniel (eind-gety parsieële druk 4.0 kPa) of propofol-sufentaniel narkose en of 
rokuronium (0.9 mg/kg) of cisatrakurium (0.15 mg/kg) te ontvang.  Alle pasiënte het 'n 
teiken-beheerde sufentaniel infusie (0.5 ng/ml).  Neuromuskulêre blokkade is waargeneem 
met behulp van aksellerometrie (TOF-GUARD, Organon) terwyl pasiënte spontaan herstel 
het tot “reeks-van-vier” verhouding (Engels “Train-of-four” ratio)  0.9 (TOFR0.9).  Data 
analise is gedoen met behulp van een- en tweerigting analise van variansie.  
 
Resultate 
Desfluraan-sufentaniel het die gemiddelde hersteltyd tot T125% en TOFR0.9 verleng in 
vergelyking met propofol-sufentaniel.  Geen interaksies is waargeneem nie.  Gemiddelde 
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verlenging van TOFR0.9 vir cisatrakurium was 41 minute (standaardafwyking 36) en vir 
rokuronium 26.6 minute (standaardafwyking 39). 
 
Bespreking 
Vorige studies kon nie vasstel of desfluraan die werkingsduur van rokuronium verleng nie.  
Ons het in hierdie studie vasgestel dat desfluraan wel 'n statisties beduidende verlenging in 
die hersteltyd van beide rokuronium en cisatrakurium veroorsaak.  Ons kon egter nie 'n 
verskil tussen die twee neuromuskulêre agente aandui nie.  'n onderskeidingsvermoëstudie 
het getoon dat ten minste 101 pasiënte per groep benodig sou word om 'n beduidende verskil 
tussen die hersteltye tot TOFR0.9 te verkry. 
 
Gevolgtrekking 
Desfluraan verleng die gemiddelde hersteltyd tot spontane herstel van neuromuskulêre 
blokkade na driedubbele ED95 dosisse van beide cisatrakurium en rokuronium.  Daar was 
egter groot interindividuele variasie ten opsigte van spontane hersteltyd.  Enige verskille in 
die gemiddelde verlenging is onwaarskynlik van kliniese belang. 
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INTRODUCTION 
History of the potentiation of the effects of neuromuscular blockers by volatile anaesthetic 
agents 
The effect of general anaesthetics on the neuromuscular junction has been studied for nearly a 
century.  A study on the effect of ether inhalation upon the skeletal motor contraction 
mechanism was published as early as 1914. (1)  Early animal model studies were later 
followed by clinical in vivo studies in an attempt to quantify this effect. 
 
For more than four decades it has been well known that clinically less neuromuscular blocker 
is required to produce neuromuscular blockade in the presence of volatile agents. (2)  Walts 
et al. studied the magnitude and duration of effect of curare in the presence of different 
anaesthetic agents and showed that, in comparison to an opioid-nitrous oxide anaesthetic, 
inhaled anaesthetic agents potentiated the twitch depression produced by curare. (3)  Waud et 
al. demonstrated that the effect of volatile agents on mammalian muscle was concentration-
dependent. (4) 
 
Physiology and pharmacology of the neuromuscular junction 
The physiology of the neuromuscular junction has been extensively studied and is well 
elucidated. (5)(6)(7)  Interestingly, initial interest in this specific area was prompted by the 
desire to explain the mechanism of action of volatile agents. 
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Acetylcholine is produced in the cytoplasm of the nerve terminal and stored in vesicles.  
These vesicles are docked to the presynaptic membrane by means of specialized proteins, 
namely, soluble N-ethylmaleimide-sensitive-attachment-protein receptors (SNARE).  These 
SNARE proteins include synaptobrevin, syntaxin and synaptosome-associated protein of 
25kd (SNAP-25).  Synaptobrevin (located on the vesicle membrane) attaches to syntaxin and 
SNAP-25 (which reside on the plasma membrane of the nerve terminal).  Synaptotagmin (a 
protein on the vesicle membrane) stabilizes the vesicle in the docked state and acts as a 
calcium sensor.  Depolarization of the motor nerve opens voltage-gated calcium channels (P-
type) which allow an influx of calcium into the terminal button.  The calcium facilitates 
exocytosis of the acetylcholine stored inside the docked vesicles.  Under experimental 
conditions, the concentration of ionized calcium in the extracellular fluid is proportional to 
the amount acetylcholine released. 
 
These acetylcholine molecules diffuse across the cleft between the terminal button and the 
muscle endplate and bind to nicotinic acetylcholine receptors (nAChR) on the post-synaptic 
membrane.  The nAChR consists of 5 subunits (α2, β, ɣ, δ or Ɛ) that are arranged to form an 
ion channel with a central pore.  Simultaneous occupation of the two binding sites for 
acetylcholine at the αƐ and αδ subunit borders results in a conformational change in the 
subunits and opening of the central pore to allow the flow of sodium, potassium and calcium 
cations along their individual concentration gradients.  This ion flow results in an end-plate 
potential that triggers the activation of peri-junctional voltage–gated sodium channels which 
results in muscle membrane depolarization.  The resultant action potential precipitates a 
sequence of events that ultimately result in muscle contraction. 
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After interacting with the binding sites on the nAChR, the acetylcholine molecules are 
released into the junctional cleft and are hydrolysed within one millisecond by 
acetylcholinesterase.  Thus under normal conditions, one molecule of acetylcholine will only 
interact with one receptor before it is destroyed. 
 
nAChR are also found on the presynaptic membrane at the neuromuscular junction.  Nervous 
tissue does not contain the genes that code for the ɣ, δ or Ɛ subunits and thus these receptors 
differ from their postsynaptic counterparts, consisting of three α and two β subunits.  Their 
function upon stimulation is to increase mobilization of vesicular acetylcholine so that more 
vesicles are readily available for docking and exocytosis of acetylcholine.  This ensures that 
the neuromuscular junction is able to function effectively even during a state of high 
frequency impulses. 
 
Non-depolarizing neuromuscular blockade is the result of competitive receptor antagonism at 
the acetylcholine binding sites on the postsynaptic nAChR.  Non-depolarizing muscle 
relaxants (NDMR) occupy the nAChR binding sites for a slightly longer period of time than 
the normal lifetime of acetylcholine.  The degree of block is therefore influenced by the 
relative concentration of acetylcholine and NDMR at the nAChR binding sites and the 
duration of time that the acetylcholine molecules reside in the junctional cleft. 
 
NDMR also bind to the α3β2 nAChR on the presynaptic membrane thus inhibiting the 
mobilization of acetylcholine vesicles in the terminal neuron.  This is manifested clinically as 
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‘fade’, which is a phenomenon of progressively decreasing twitch heights seen with Train-of-
Four and tetanic stimulation in the presence of NDMR. 
 
If a single twitch stimulus is applied directly after a tetanic stimulus, in the presence of a 
NDMR, the twitch height of the single twitch will be significantly larger than the 
corresponding pre-tetanic twitch heights.  This phenomenon of post-tetanic potentiation is 
explained by the increased concentration of calcium ions in the terminal neuron that occurs 
immediately after tetanus.  Calcium ions enter the cytoplasm of the nerve with every 
stimulus.  These ions cannot be removed from the cytoplasm as quickly as they enter during 
the tetanic stimulation and therefore the ions accumulate.  The higher concentration of 
calcium ions in the cytoplasm results in more acetylcholine being released into the junctional 
cleft.  In turn, the increased amount of acetylcholine momentarily partially antagonises the 
neuromuscular blockade by the NDMR and is demonstrated clinically as post-tetanic 
potentiation. 
 
Evaluation of neuromuscular junction 
Monitoring the neuromuscular junction involves the stimulation of a peripheral nerve using a 
supra-maximal stimulus and measuring the evoked muscular response.  The most common 
method of applying the stimulus is by means of electrical nerve stimulation.  The stimulus 
(fulfilling specified characteristics to prevent repetitive firing) must be of sufficient intensity 
to depolarise all the nerve fibres that supply the muscle simultaneously thereby causing a 
maximal motor response.  To ensure a truly maximal response, a stimulus that is 20-25% 
greater than that which is necessary for a maximal response is required. 
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A variety of patterns of stimulation may be employed. 
Single twitch stimulation consists of a single supra-maximal stimulus being applied to a 
peripheral nerve.  The frequency of the stimulation ranges from 1.0 – 0.1 hertz (Hz).  The 
evoked force of the muscle response is measured and the amplitude of the twitch height is 
compared to the control response measured prior to neuromuscular blocker administration.  
The evoked response is expressed as a percentage of the control response e.g. the first twitch 
response is 25% of the control height (T125%) 
 
Tetanic stimulation involves electrical stimulation at a very rapid rate (30-100Hz) usually for 
a 5 second period.  Fade of muscle contraction occurs during tetanic stimulation in the 
presence of NDMR, and this phenomenon has been used to demonstrate residual paralysis.  
However, the stimulation is painful and thus its use is limited to anaesthetized patients.  
Furthermore, repeated tetanic stimulation results in partial recovery of the stimulated muscle, 
which can be clinically confusing.  More appropriate methods to detect residual 
neuromuscular blockade by NDMR include evaluation of fade during “double-burst” 
stimulation (8) and Train-of-Four stimulation (see below). 
 
Train-of-Four (TOF) stimulation consists of four supra-maximal electrical stimuli applied at a 
frequency of 2Hz.  The evoked muscle response is observed and, in the presence of NDMR, 
exhibits fade.  The train-of-four ratio (TOFR) is calculated by dividing the amplitude of the 
4th response by the amplitude of the 1st response.  During control conditions, the TOFR will 
be 1.0 and in the presence of NDMR, fade is represented by a decreased ratio.  Thus the 
TOFR varies inversely with the degree of blockade due to a non-depolarizing agent.  This 
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method of stimulation is commonly used in clinical practice as it has the advantages of not 
requiring the control response to be assessed prior to the administration of the NDMR and it 
is less painful than tetanic stimulation. 
 
In anaesthesia, four clinical levels of neuromuscular blockade may be demonstrated. (8) 
Intense neuromuscular blockade occurs within the first few minutes of administration.  It is 
characterized by no response to nerve stimulation, regardless of the pattern of stimulation.  
During deep neuromuscular blockade, no response to TOF stimulation is elicited.  However, 
after a tetanic stimulation, single twitches may be observed.  Moderate blockade begins when 
a twitch response is demonstrated in response to the first stimulus during TOF stimulation.  
There is gradual return of four responses during this period and the number of responses 
elicited show a relationship with the degree of blockade.  The presence of only one evoked 
response correlates with a 90-95% blockade of nAChR in the neuro-muscular junction and 
four evoked responses correspond with 60-85% neuromuscular blockade.  The return of the 
fourth response indicates the recovery phase.  A TOFR 0.7 corresponds clinically with a 
patient who is able to cough and lift his/her head for more than 5 seconds.  However, it has 
been demonstrated that at TOFR < 0.9 patients may still have diplopia, pharyngeal 
dysfunction with danger of aspiration, and decreased carotid body chemosensitivity to 
hypoxia.  (9)  Thus, TOFR should be at least 0.9 to exclude residual paralysis. 
 
Good Clinical Research Practice (GRCP) in pharmacodynamic studies of neuromuscular 
blocking agents was published with the aim to establish internationally acceptable guidelines 
for studies in neuromuscular blocking agents. (10)  These guidelines suggest that all durations 
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and intervals should be referenced to a defined baseline control value.  The clinical duration 
of block should be measured from the start of drug administration until 10% or 25% T1 
recovery.  The initial recovery phase should be described by the time from 25% twitch 
recovery to 75% twitch recovery, i.e. interval 25-75%.  Complete recovery time should be 
described by the time from 25% twitch recovery to TOFR 0.8, i.e. interval 25% - TOFR0.8 
 
A variety of methods are available to record evoked responses. (8) 
Mechanomyography measures the evoked mechanical response of the muscle in response to a 
supramaximal stimulus applied to a peripheral nerve via cutaneous electrodes.  Most 
commonly, the ulnar nerve is stimulated evoking a response in the Adductor pollicis muscle, 
which in turn acts on a force-displacement transducer that converts the mechanical signal into 
an electrical signal.  A pre-requisite for reproducible measurements is that isometric muscle 
contraction should be evoked.  This is achieved by applying a small preload (200-300g of 
resting tension) to the thumb.  Mechanomyography has been used for many years for the 
precise quantification of neuromuscular blockade and may be considered to be the “gold 
standard”. (10)  However, early models were cumbersome and impractical for use in 
operating theatres. 
 
Electromyography measures the evoked electrical response, that is, the compound action 
potentials produced in the muscle in response to a supra-maximal stimulus applied to the 
peripheral nerve via cutaneous electrodes.  Electromyographic recording equipment is not as 
bulky as mechanomyography and easier to assemble.  However, it is subject to numerous 
sources of inaccuracy, such as interference, direct muscle stimulation and signal drift. (11) 
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Acceleromyography measures the acceleration of the muscle in response to a supra-maximal 
stimulus applied to the peripheral nerve via cutaneous electrodes. (12)  Newton’s second law 
of motion states that force is directly proportional to acceleration (force = mass x 
acceleration).  A piezoelectric ceramic wafer is simply taped to the thumb (an unchanging 
mass).  Thus, evoked movement of the Adductor pollicis causes the piezoelectric wafer to 
generate an electric potential that is proportional to the degree of acceleration.  A 
standardized elastic preload applied to the thumb with the acceleromyography transducer 
ensures that the thumb returns to its initial position after each response.  Acceleromyography 
was developed as a more convenient method of monitoring the neuromuscular junction in 
operating theatres.  The TOF-GUARD® monitor (Organon Teknika, Turnhout, Belgium) is a 
commercially available acceleromyographic monitor.  Acceleromyography is not 
interchangeable with mechanomyography or electromyography and the temptation to directly 
compare results from different methods should be resisted. (13) 
 
Kinemyography or piezoelectric neuromuscular monitoring utilizes a movement sensor and 
should be differentiated from acceleromyography.  A piezoelectric polymer is placed between 
the thumb and forefinger.  Movement of the thumb causes the redistribution of electrical 
charge on the sensor which is computed to a TOFR. (14) 
 
Consideration of potential sources of error 
It must be appreciated that the consistency of measurements made by the TOF-GUARD® 
may be compromised by sources of baseline signal ‘drift’.  Thus correct instrument 
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calibration, together with specific measures to limit individual variability and improve 
baseline stabilization, must be undertaken in order to obtain reliable measurements.   
 
Repetitive indirect stimuli of skeletal muscle may cause potentiation of the evoked twitch 
tension.  This effect has been termed the “staircase phenomenon” and is applicable to 
acceleromyographic as well as mechanomyographic monitoring techniques. (9)  Kopman 
found that the magnitude of twitch augmentation is directly related to the frequency of 
stimulation.  Sixty stimuli per minute (1 Hz) produce a larger effect than 16 stimuli per 
minute, which in turn produces a greater effect than six stimuli per minute (0.10 Hz).  A five-
second 50-Hz tetanus administered before initial twitch calibration has been shown to 
considerably shorten the time required to achieve baseline stability and thus reduce individual 
variability. (15)  The staircase phenomenon is not manifested during the fade of twitch 
responses that occurs during TOF stimulation and therefore, does not affect the TOFR. 
 
In the absence of neuromuscular block, TOFR may exceed values of 1.30, and in the absence 
of any preload applied to the thumb the TOFR ratio averages approximately 1.15–1.20. (9)  
Although the mechanism for this TOF augmentation has not been elucidated, it is reduced if a 
small elastic preload is applied to the thumb. (9)  Dubois (16)(17) described a method to fix 
the arm and hand while creating a thumb preload within a “TOF tube" in order to optimize 
the accuracy and repeatability of accellerometry measurements. 
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Effects of interactions of volatile agents on NDMR 
Individual volatile agents differ clinically in the magnitude by which they potentiate the 
neuromuscular blockade induced by NDMR. (2)  For example, Miller et al. (18) 
demonstrated that 3.3 times more d-Tubocurarine was needed to obtain a 50% reduction in 
twitch height during halothane anaesthesia than during isoflurane anaesthesia.   
 
The potentiation of non-depolarizing neuromuscular blockade by volatile agents includes the 
following three phenomena: (19) 
 Decreased dose of neuromuscular blocker to produce similar clinical effect (i.e. 
increased potency) 
 Shortened onset of action of neuromuscular blockade,  
 Prolonged duration of action of the relaxant and prolonged recovery from the effects 
of neuromuscular blockade.  
 
Numerous studies have investigated these aspects of the interaction between volatile 
anaesthetic agents and NDMR.  Various investigators have attempted to quantify these 
effects.  However varied results have been achieved.  The pertinent studies are discussed in 
the following section and summarized in Table A1. 
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Studies investigating the effects of modern volatile anaesthetic agents on modern 
neuromuscular blockers 
Rupp et al. (20) randomized 40 patients to receive 1.25 minimum alveolar concentration 
(MAC) halothane or enflurane (in 60% nitrous oxide) for 30 minutes prior to the 
administration of single bolus of atracurium (randomized to 50, 60, 70, 80, 90 or 100 μg/kg).  
They measured evoked twitch height responses of the Adductor pollicis using 
mechanomyography.  They were unable to demonstrate a significant difference in the dose-
response regression lines for halothane versus enflurane.  However, when the results were 
analysed together with the results of a previously published study by the same lead author 
(21) that studied the effects of atracurium administered with 1.25 MAC isoflurane or fentanyl 
(both in 60% nitrous oxide), they demonstrated a statistically significant difference in the 
potency of atracurium administered in the presence of enflurane or isoflurane compared to a 
fentanyl-nitrous oxide anaesthetic.  They estimated that the potentiation of atracurium by 
volatile agents was probably not more than 20%.  They were unable to demonstrate any 
difference in the onset time of atracurium when administered in the presence of either one of 
the four different anaesthetics.  Rupp et al. also measured the time from injection of the 
allocated single bolus of atracurium until the evoked twitch height of the Adductor pollicis 
was 95% of control as measured by mechanomyography.  Using linear regression, they 
interpolated the plots of duration of action versus peak effect (defined as maximum 
percentage depression of twitch tension) for each group and then calculated the duration of a 
50% block (Duration50 – see Table 4).  No significant difference in duration of action of 
atracurium was demonstrated between the enflurane and halothane groups.  Again, the results 
of this study (comparing atracurium in halothane or enflurane) were analysed with the results 
of their previously published study (comparing atracurium in isoflurane or fentanyl).  In this 
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manner they demonstrated a 33% increase in the duration of atracurium when administered 
together with enflurane compared to a fentanyl-nitrous oxide anaesthetic which is statistically 
significant. 
 
These two studies (20)(21) therefore demonstrated that modern volatile anaesthetic agents 
increased the potency and duration of action of atracurium. 
 
Ten years later, Wright et al. (22) performed a cross-over study in 16 patients to examine the 
effect of 1.25 MAC desflurane as well as 1.25 MAC isoflurane on vecuronium.  The cross 
over design was intended to reduce the large inter-individual variation seen in the dose-
response curve of vecuronium.  All subjects were anaesthetized with the inhaled anaesthetic 
agents for >60 minutes prior to the administration of vecuronium to allow equilibration of the 
anaesthetic agents at the neuromuscular junction.  They measured evoked Adductor pollicis 
twitch tension using mechanomyography.  Fifty percent of participants were enrolled in 
potentiation studies in which 10μg/kg boluses of vecuronium were repeatedly administered 
until 90% twitch depression was achieved, at which point a vecuronium infusion was initiated 
and adjusted to maintain stable twitch depression at 80-90% of control.  Wright et al. 
demonstrated that subjects displayed 20% greater twitch tension depression after 
administration of vecuronium when anaesthetized with desflurane compared to isoflurane.  
The remaining 50% of participants were enrolled in onset and duration studies in which a 
single bolus of vecuronium (100μg/kg) was administered and twitch tension was recorded 
until spontaneous recovery to 80-100% of control.  Wright et al. demonstrated a faster onset 
time (defined as time from administration of vecuronium bolus to 12 seconds after last 
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detectable twitch response) for maximal muscle relaxation by vecuronium in the presence of 
desflurane versus isoflurane.  They showed a significant increase in time for recovery to 
T125% and to T190% as well as the recovery interval from T125% to T175% (T125-75%) of twitch 
height in the desflurane group versus the isoflurane group.  This study (22) demonstrated that 
desflurane increased the potency, onset time and duration of vecuronium to a greater degree 
than isoflurane.  
 
Kumar et al. (23) randomized 68 patients to receive desflurane or isoflurane (both 1 MAC in 
66% nitrous oxide).  Ten minutes after stabilization of the end-tidal concentration of the 
volatile agent, all patients received a single bolus of rocuronium.  The neuromuscular 
junction was monitored using mechanomyography and TOF stimulation.  Seventy percent of 
the participants in the study were enrolled in the potentiation studies and were randomly 
allocated to single rocuronium boluses of 75, 150, 225 or 300 μg/kg.  The different doses of 
NDMR administered allowed for construction of a dose-response curve (using least squares 
regression analysis).  The curves for isoflurane and desflurane did not differ in their slopes or 
intercepts and thus indicating no difference in potentiation.  The remaining thirty percent of 
the participants in the study were enrolled in onset and duration studies.  These patients 
received a single bolus of 0.6mg/kg of rocuronium.  Patients in the desflurane and isoflurane 
groups showed similar onset times by rocuronium (defined as time from administration to 
maximal effect).  Kumar et al. implied that their study demonstrated longer recovery times 
(T125%, T190%, TOFR 0.7, recovery interval T125%-75%) in the presence of desflurane in nitrous 
oxide compared to isoflurane.  However their results did not achieve statistically significance.  
On examining the data presented in their paper (Table 4, page 489), we calculated the 95% 
confidence intervals of the difference between means for time to spontaneous recovery to 
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TOFR 0.7 and it is -0.19 to 28,02 minutes.  This interval includes zero indicating that there is 
no difference between the groups.  However, the interval includes 28 minutes which could be 
a clinically significant difference.  A power calculation based on the published data reveals 
that in order to demonstrate a difference with an alpha of 0.05 and a power of 80%, the study 
would need 18 patients per group.  In this study only 10 patients were included in each group 
for the onset and duration studies and therefore it is probably underpowered.  Ultimately, this 
study (23) could not demonstrate a difference in the potency, onset or duration of rocuronium 
in the presence of desflurane or isoflurane. 
 
Lowry et al. (24) also studied rocuronium and randomized 102 patients anaesthetized with 
66% nitrous oxide in oxygen to 1.5  MAC of sevoflurane or isoflurane, or a propofol 
infusion.  Adductor pollicis muscle mechanomyography was utilized and the muscle relaxant 
was administered 10 minutes after initiation of the administration of the volatile agent.  
Seventy percent of subjects in the study were enrolled in the potentiation studies and were 
randomized to receive a single bolus of rocuronium (75, 150, 225 or 300 μg/kg) to construct a 
dose-response curve.  No significant difference in the gradients of the dose-response curves 
was demonstrated.  However, comparison of the estimated ED50 for rocuronium in each group 
demonstrated a significant difference between the sevoflurane and the propofol groups.  
Sevoflurane increased the potency of rocuronium in this study.  Thirty percent of subjects in 
the study were enrolled in the onset and duration studies and received a single bolus of 
rocuronium (0.6mg/kg).  There was no difference in onset time (defined as time from 
administration to maximal blockade).  Lowry et al. did demonstrate significantly prolonged 
recovery (TOFR 0.8, T125%-75%) of rocuronium in the sevoflurane group versus the propofol 
and isoflurane groups.  The isoflurane group demonstrated marginally prolonged duration 
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from administration of rocuronium to T190% recovery and time to TOFR 0.8.  Therefore this 
study (24) demonstrated that sevoflurane increased the potency and duration of action of 
rocuronium compared to isoflurane and propofol.  No difference in the onset of action was 
demonstrated 
 
The contrasting results in these four studies may be explained by the difference in the 
duration of time that the patients were exposed to the volatile agents before the NDMR were 
administered.  The former two studies (20)(22) allowed 30 and 60 minutes respectively to 
allow equilibration of the anaesthetic agents at the neuromuscular junction.  In contrast, the 
latter two studies (23)(24) only allowed 10 minutes each for equilibration. 
 
Wulf et al. (25) investigated rocuronium in 80 patients during anaesthesia with 1.5 MAC 
desflurane, sevoflurane, isoflurane or total intravenous anaesthesia (TIVA) using 
propofol/fentanyl (all in 70% nitrous oxide).  While previous studies had prescribed a 
minimum mandatory interval between the onset of anaesthesia and administration of the 
muscle relaxant to allow for equilibration of the volatile agents in the neuromuscular 
junction, this was not done in this study.  The authors argued that this was in keeping with 
clinical practice.  They stabilized the arm using specialized arm board.  TOF stimulation of 
the ulnar nerve was administered and the response of Adductor pollicis was assessed using 
acceleromyography (TOF-GUARD®).  A cumulative bolus technique was used to ensure 
equivalent doses in terms of the end-point achieved in individual patients.  The calculated 
ED50s showed that desflurane and sevoflurane significantly increase the potency of 
rocuronium when compared to TIVA.  They expressed the degree of potentiation of volatile 
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agent as the ratio of ED50 of rocuronium during TIVA divided by ED50 of rocuronium during 
volatile anaesthesia.  In this study, the degree of potentiation was 1.6 for desflurane, 1.3 
sevoflurane and 1.2 isoflurane.  Recovery end-points were measured and did not show 
significant prolongation in the duration of action of rocuronium in the volatile anaesthetic 
groups. 
 
In a similarly designed study, also using a cumulative bolus technique and 
acceleromyography, Wulf et al. (26) studied cisatracurium in 84 patients during anaesthesia 
with 1.5 MAC desflurane, sevoflurane, isoflurane or total intravenous anaesthesia (TIVA) 
with propofol and fentanyl (all in 70% nitrous oxide).  There was also no minimum 
mandatory interval prescribed between the onset of anaesthesia and administration of 
rocuronium.  They demonstrated a more pronounced depression of T1 in the volatile 
anaesthetic groups compared to the TIVA group and demonstrated that the degree of 
potentiation (ratio of ED50 during volatile anaesthesia/ED50 during TIVA) of cisatracurium 
was 1.4 for desflurane, sevoflurane and isoflurane.  Recovery end-points were measured and 
also did not show significant prolongation in the duration of action of cisatracurium in the 
volatile groups.  As repetitive incremental dosing was used in this study, the authors 
speculated that had the NDMR been given as equivalent single “bolus” doses, the differences 
in duration of action may have become evident.   
 
Therefore these two studies (25)(26) demonstrated that the potency of rocuronium and 
cisatracurium was increased by several volatile anaesthetic agents compared to TIVA.  
Prolongation of the duration of action of the muscle relaxants was not demonstrated. 
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Amin et al. (27) randomized 80 patients to four groups to receive either cisatracurium or 
rocuronium, during anaesthesia with either 2 MAC sevoflurane or propofol TIVA (all in 50% 
nitrous oxide).  The neuromuscular junction was monitored with acceleromyography and 
TOF stimulation.  However the study does not comment on how the TOF-GUARD® was 
calibrated or set up technically.  The NDMRs were administered incrementally until 95% 
twitch depression was achieved.  They constructed cumulative dose-response curves and 
demonstrated that sevoflurane anaesthesia resulted in an approximately 20% decrease of the 
ED50 and ED95.  They found no difference in the degree of depression between the two 
muscle relaxants.  Recovery end-points were measured and results demonstrated that the 
recovery index T125-75% and time to spontaneous recovery of TOFR of 0.70 were significantly 
prolonged in the sevoflurane groups compared to propofol groups.  These endpoints were 
also significantly longer in the cisatracurium group compared to the rocuronium group.  
Therefore this study (27) demonstrated that the potency and duration of action of rocuronium 
and cisatracurium was increased by sevoflurane (at 2MAC) compared to propofol. 
 
Using electromyography to monitor the neuromuscular junction, Bock et al. (28) randomized 
84 patients to receive 1.25 MAC isoflurane, desflurane, sevoflurane or propofol (all in 60% 
nitrous oxide).  Inhaled anaesthetic agents were administered for 40 minutes prior to the 
administration of rocuronium to allow equilibration of anaesthetic agents at the 
neuromuscular junction.  At this point the electromyography was re-calibrated and a single 
dose of 0.1, 0.15 or 0.2mg/kg rocuronium was administered.  After maximal depression of 
the twitch response was recorded a second dose of rocuronium was administered so that all 
subjects received a cumulative bolus dose of 0.3mg/kg of rocuronium.  After recovery of T1 
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to 5% of control twitch height, a rocuronium infusion was initiated and adjusted to maintain 
T1 at 5-10% of control twitch height.  Dose-response curves were constructed and used to 
calculate ED50 and ED90 for rocuronium.  They demonstrated a leftward shift in the dose 
response curve of rocuronium when administered in the presence of isoflurane, desflurane 
and sevoflurane compared to propofol.  The desflurane group had the lowest ED90.  They 
could not demonstrate a statistically significant difference in the ED50 or ED90 for rocuronium 
in the presence of any of the volatile groups compared to the propofol group, despite each 
group consisting of 21 patients.  The infusion rate of rocuronium required to maintain T1 at 
less than 10% of control was reduced during the volatile anaesthetics compared to the 
propofol group, thus suggesting that the potency of rocuronium was increased by 30-40% in 
the presence of a volatile agent.  Bock et al. measured recovery end points but could not 
demonstrate a statistically significant prolonged spontaneous recovery for rocuronium in the 
presence of desflurane, sevoflurane, isoflurane compared to propofol.  Confidence intervals 
are not provided and a posthoc power analysis was not performed, thus it is possible that the 
study was underpowered.  Therefore this study (28) demonstrated that volatile anaesthetic 
agents potentiate the potency of rocuronium. 
 
Similarly, Hemmerling et al. (29) randomized 56 patients to receive isoflurane, sevoflurane, 
desflurane or propofol infusions.  However, in contrast to the other studies where nitrous 
oxide was used, all anaesthetics in this study were administrated in oxygen and air.  The 
neuromuscular junction was monitored using electromyography and TOF stimulation.  
Attention was paid to calibration of the instrument; however, this did not include a stabilising 
tetanic stimulus.  There was no standardized time of anaesthesia prior to the administration of 
cisatracurium.  They used a closed-loop feedback system to control administration of 
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cisatracurium to maintain the first twitch response to a TOF stimulus at 10% of its control 
value.  Their results showed that, in comparison to propofol, the volatile anaesthetic agents 
resulted in a cumulative dose reduction of cisatracurium of 42% with sevoflurane, 41% with 
isoflurane and 60% with desflurane, all of which are statistically significant.  The dose 
reduction demonstrated in the desflurane group compared to the other volatile anaesthetic 
agents is also statistically significant.  Therefore this study (29) demonstrated that volatile 
anaesthetic agents increased the potency of cisatracurium compared to propofol. 
 
Stout et al. (30) randomized 40 patients to receive either desflurane or propofol.  All 
anaesthetics were supplemented by 50% nitrous oxide and intravenous boluses of fentanyl 
were administered at the discretion of the anaesthetist.  After 3 minutes of calibration of the 
electromyographic neuromuscular junction monitoring equipment, a single rocuronium bolus 
(0.6mg/kg) was administered.  After spontaneous recovery of the T1 to 10% of its control, an 
infusion of rocuronium was commenced and titrated to maintain T1 at 10%.  They showed 
that the required infusion rates of rocuronium were 67% less in the desflurane group 
compared to the propofol group.  This statistically significant difference became evident 
within the first 30 minutes of administration of the infusion.  Onset times were measured in 
this study and were defined as the time from administration of rocuronium bolus to T1 10%.  
Surprisingly, they found that the onset times in the desflurane group were 67% longer than in 
the propofol group.  This was attributed to the increase in sympathetic tone that may occur 
with sudden rapid increase in the end-tidal concentration of desflurane.  They suggested that 
this resulted in superficial vasoconstriction and delay in delivery of rocuronium to the 
Adductor pollicis that was being monitored.  The infusion of rocuronium was discontinued 30 
min prior to the end of surgery and spontaneous neuromuscular recovery was recorded for as 
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long as possible.  None of the recovery end-points measured (time from discontinuation of 
rocuronium infusion to T125%, 50%, 75% and 90%) demonstrated statistically significant differences 
between the groups, although the study was probably underpowered to evaluate spontaneous 
recovery end-points.  The authors noted that the number of patients that achieved T175% and 
T190% spontaneously in each group were too small for statistical comparison.  Therefore this 
study (30) demonstrated that desflurane increased the potency of rocuronium compared to 
propofol.   
 
Factors that affect the degree of potentiation of NDMR  
As described above, various studies have attempted to quantify the potentiation of NDMR by 
inhaled anaesthetic agents and that these have yielded varied results.  The inconsistencies in 
the studies may be explained by differences in study design and/or end-points examined. 
 
The magnitude of potentiation is influenced by several factors: 
 the partial pressure at which the volatile agent is administered, 
 the duration of exposure to the volatile agent (before administration of NDMR), 
 the specific muscle relaxant  
 the specific volatile agent  
 
These aspects are discussed in the following sections: 
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 The influence of volatile anaesthetic agent partial pressure 
The potentiation of muscle relaxants by volatile agents is dose-dependent.  This has been 
demonstrated in vitro as well as in vivo. (3)  Waud et al. (4) showed that volatile agents 
depress the ability of isolated mammalian muscle to undergo depolarization when exposed to 
a cholinergic agonist.  This effect was concentration-dependent.  Gencarelli et al. (31) 
administered a constant-rate infusion of d-Tubocurarine (adjusted to produce a constant 
twitch tension 10% of control) and an end-tidal concentration of enflurane (ETEnf) at 2.2% for 
60 minutes.  While the infusion of muscle relaxant was continued at the same rate, the 
enflurane concentration was decreased to ETEnf 1.35% for the following 60 minutes and then 
to ETEnf 0.5% for the final 60 minutes.  Blood samples were taken at 60 minute intervals and 
radioimmunoassays performed to measure serum d-Tubocurarine levels.  While the serum d-
Tubocurarine levels were demonstrated to remain constant (approximately 0.2µg/ml), the 
decreasing enflurane concentration resulted in a significant decrease in the degree of 
neuromuscular blockade.  At ETEnf 2.2% twitch tension (as measured by mechanomyography 
at the Adductor pollicis muscle) was 8% of the control twitch tension.  At ETEnf, 1.35% twitch 
tension increased to 57% of control and at ETEnf 0.5% it increased further to 91% of control. 
 
 The influence of the duration of administration of volatile anaesthetic agent 
The duration of exposure to the volatile agent influences the degree of potentiation displayed.  
Motamed et al. (32) demonstrated that there was a time-dependent potentiation of 
mivacurium induced neuromuscular blockade by sevoflurane and isoflurane compared with 
propofol.  In this study, all patients were induced with propofol and fentanyl and after loss of 
consciousness, the neuromuscular junction was monitored with accelerometry and TOF 
stimulation.  Details about calibration and stabilization of the monitored arm are not 
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available.  All patients received an intubating dose of mivacurium (0.25mg/kg) and after 
tracheal intubation, were randomized to receive isoflurane (ETIso 1.2%) or sevoflurane 
(ETSevo 1.9%) or propofol (all in 50% nitrous oxide).  After spontaneous recovery of T1 to 
5% of its control, a mivacurium infusion was initiated at 10μg/kg/min and the infusion was 
manually adjusted to maintain T1 at 5-10% of its control value.  The mivacurium 
requirements decreased progressively with time in all groups with the most meaningful 
changes occurring in the first 15 minutes after initiation of the mivacurium infusion.  This 
early decrease in the mivacurium infusion rate was greater in the groups that received a 
sevoflurane or isoflurane anaesthetic.  A statistically significant difference was demonstrated 
between the volatile anaesthetic agents and the propofol group at 15 minutes.  The infusion 
requirements in the volatile groups continued to decrease, albeit at a slower rate, and at 90 
minutes, the mivacurium infusion rate in the propofol group was four times higher than the 
infusion rate in the sevoflurane group.   
 
 The influence of the type of muscle relaxant on the interaction between 
muscle relaxant and volatile anaesthetic agent 
The type of muscle relaxant used may influence the degree of potentiation measured.  Rupp 
et al. (20) first suggested that different NDMR may be potentiated to different extents when 
they compared data from different studies by the same investigators and noted that 
atracurium and vecuronium appeared to be less affected by volatile agents than t-
Tubocurarine or pancuronium.  Work by Wulf et al. (25)(26) suggests that rocuronium may 
be more susceptible to potentiation by desflurane than cisatracurium.  Amin et al. (27) 
directly compared the degree of potentiation exerted by sevoflurane on rocuronium and 
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cisatracurium and demonstrated that the duration of action of cisatracurium in the presence of 
sevoflurane was significantly longer than that of rocuronium. 
 
 Influence of the type of volatile agent 
It appears that specific volatile agents differ with regard to the degree of potentiation that 
they exert on the effect of neuromuscular blockers.  Not all studies yield identical results.  
This is attributed to differing methodologies and several of the studies lack statistical power.  
However, it seems that most studies agree on the order that the volatile anaesthetics may be 
ranked in terms of their potentiating effect on neuromuscular blockers.  Desflurane has been 
shown to display the greatest degree of potentiation of NDMR, followed by sevoflurane > 
isoflurane > halothane > nitrous oxide-barbiturate-opioid or propofol anaesthesia. (22) (23) 
(25) (29) 
 
Proposed mechanism by which volatile agents potentiate the effect of neuromuscular 
blockers 
The exact mechanism of enhancement of non-depolarizing muscle relaxant-induced 
neuromuscular blockade by volatile anaesthetic agents is under debate.  Postulated 
mechanisms are varied and include: 
 direct synergistic effects at the level of the nAChR,  
 prejunctional effects of inhaled anaesthetic agents,  
 pharmacodynamic interaction by means of increased blood flow to muscles 
under anaesthesia, and  
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 centrally mediated relaxation by inhaled anaesthetic agents including the 
preferential effect of inhaled anaesthetic agents on the spinal cord and central 
pattern generator. (27) (33) 
 
Using an isolated mammalian muscle model, Waud et al. (4) concluded that both 
neuromuscular blockers and volatile anaesthetics inhibit depolarization at the neuromuscular 
end-plate.  While neuromuscular blockers prevent the interaction between acetylcholine and 
the nAChR, the volatile agents depress depolarization at a step distal to the receptor.  They 
suggested that depolarization of the muscle membrane was inhibited in the presence of 
volatile agents despite the nAChR being stimulated by its agonist. 
 
Early pharmacokinetic studies with rocuronium suggested that volatile anaesthetics did not 
significantly influence the pharmacokinetics of the muscle relaxant (i.e. did not change the 
rate of disappearance of rocuronium from the plasma) and that volatile anaesthetic-induced 
potentiation of the neuromuscular block could probably be explained by increased sensitivity 
of the neuromuscular junction for the relaxant (i.e. decrease in the EC50). (34)  Thus volatile 
agents probably influence muscle relaxants at a pharmacodynamic level. 
 
Evidence in support of this supposition was produced by Paul et al. (6) who studied the 
inhibitory effects of two NDMR (d-Tubocurarine and vecuronium) in isolation and in the 
presence of two volatile anaesthetics agents (sevoflurane and isoflurane) in an in vitro model 
designed to evaluate their interaction at the nAChR level.  Their work showed that exposure 
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of the model to volatile agents enhanced the inhibitory effects of the neuromuscular blockers 
on the nAChR and they suggested that volatile anaesthetics may enhance the affinity of the 
nAChR for NDMR.  The augmentation of effect achieved statistical significance at all 
concentrations of muscle relaxant studied.  This potentiation was most impressive at small 
concentrations of muscle relaxant. 
 
The magnitude of potentiation is dependent on the aqueous concentration of the volatile 
agent.  Motamed et al. demonstrated that the anaesthetic potency of the individual volatile 
agents (in terms of MAC) did not correspond to their muscle-relaxing properties.  They 
suggested that the volatile agents when used clinically, are equipotent in their ability to affect 
the nAChR, but the more clinically pronounced effects of some volatile agents may be 
explained in terms of the aqueous concentration of the volatile anaesthetic achieved.  Less 
potent anaesthetics (i.e., desflurane in contrast to isoflurane) appear to exert a greater effect 
because they are administered at greater partial pressures and therefore result in greater 
aqueous concentrations.  In addition, desflurane and sevoflurane have low blood/gas and 
tissue/gas solubility which results in more rapid equilibration between the end-tidal partial 
pressure and the volatile agent tension at the neuromuscular junction compared to more 
soluble volatile anaesthetics.  Thus a greater aqueous concentration at the nAChR is achieved 
more quickly, resulting in a greater clinical effect. (32) 
 
Effect of propofol, sufentanil and nitrous oxide on neuromuscular function 
It has been shown that propofol and sufentanil do not contribute to the effects of 
neuromuscular blocking agents. (35)  While nitrous oxide (N2O) (70% inspired) was 
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previously considered to not have an effect on neuromuscular blockade (36), recent evidence 
suggests that N2O has a potentiating effect on neuromuscular block.  It has been 
demonstrated to decrease the ED50 of rocuronium by approximately 20%. (37)  It is 
interesting to note that most of the studies reviewed in this paper used nitrous oxide (N2O) 
(50-70%) in all groups.  This may have influenced their results, especially with regard to the 
studies investigating the relative potencies of the various volatile anaesthetics, of which some 
did not achieve statistical significance.   
 
NDMR used in this study 
NDMR are classified into two chemical classes, namely steroidal compounds and 
benzylisoquinolinium compounds. 
 
Rocuronium is the least potent NDMR available commercially.  It is a steroidal relaxant of 
intermediate duration, thus similar in structure to, but less potent than pancuronium and 
vecuronium.  The ED95 of rocuronium is 0.3 mg/kg.  The recommended dose for tracheal 
intubation is 0.6 mg/kg body weight (thus 2xED95) after which adequate conditions for 
laryngoscopy and tracheal intubation should be established within 90 seconds.   
 
Cisatracurium is the most potent commercially available neuromuscular blocking agent with 
an ED95 of 0.05 mg/kg.  It is a benzylisoquinolinium compound and is one of the 10 stereo-
isomers of atracurium.  Its onset time and duration of effect are slightly longer than that of 
atracurium.  The recommended dose for tracheal intubation is 0.15 mg/kg body weight (thus 
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3xED95) after which adequate conditions for laryngoscopy and tracheal intubation should be 
established within 3 minutes.   
 
Studies have investigated and compared the duration of action of rocuronium and 
cisatracurium.   
 
Scultz et al. (38) used mechanomyography to study the duration of action of rocuronium in 
the presence of TIVA (in 66%N2O) and demonstrated the median time from administration of 
the NDMR to spontaneous recovery to TOFR 0.8 for rocuronium 0,9mg/kg was 73min (range 
39-127, n=18).  The very wide spread in the range of results should be noted.  Addamus et al. 
(39) used kinemyography and compared the clinical duration and time to spontaneous 
recovery after rocuronium in young (age 20-40 years) and older patients (age 60-75 years) of 
both genders during TIVA.  Statistically and clinically significant differences in the clinical 
duration of neuromuscular blockade and the complete recovery time were demonstrated 
between males and females, as well as between the young and the elderly.  The longest times 
and most heterogeneous results were demonstrated in the elderly female group. [Time to 
TOFR0.9 after 2xED95 rocuronium:  young males 59 min (interquartile range 51-67 min); 
elderly female 128 min (interquartile range 94-137 min) p<0.05]   
 
The pharmacodynamics of cisatracurium were studied by Belmont et al. (40) in patients 
receiving a barbiturate and opioid anaesthetic in 70% N2O.  Using mechanomyography, the 
mean time from injection of cisatracurium to spontaneous recovery to TOFR0.7 was 
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determined.  After cisatracurium 0.1mg/kg (thus 2xED95), the mean time of this variable was 
66.7min (SE±4.9, n=8) and after cisatracurium 0.2mg/kg (thus 4xED95) was 89.9min 
(SE±3.4, n=10). 
 
Adamus et al. (41) used kinemyography to compare the duration of action of cisatracurium 
and rocuronium in the presence of TIVA (no N2O was used).  They found no difference in the 
clinical duration of neuromuscular blockade or the complete recovery time after 3xED95 
doses of rocuronium and cisatracurium.   
 
Purpose of this study 
In summary, volatile anaesthetic agents potentiate the potency 
(20)(22)(24)(25)(26)(27)(28)(29)(30) and the duration of action of NDMR. 
(20)(22)(23)(24)(27)  Desflurane appears to cause the greatest degree of potentiation of the 
neuromuscular blocking drugs compared to other volatile anaesthetic agents. (23)(29)  
Studies conducted by Wulf et al. (25) (26) could not demonstrate significant potentiation of 
duration of action of the NDMR by volatile agents, but suggest that desflurane may have a 
more significant effect on rocuronium than cisatracurium in terms of potency.  However, 
Amin et al. (27) showed that sevoflurane prolonged the time to recovery after cisatracurium 
more than after rocuronium.  No previous study has compared the degree of potentiation 
exerted by desflurane on the highly-potent versus the less-potent NDMR.  The purpose of this 
study was to determine whether desflurane (in an oxygen and air mixture) prolongs the 
effects of rocuronium and cisatracurium to the same or to a greater degree.  The hypothesis 
was that there would be no difference. 
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METHODOLOGY 
This prospective randomized clinical trial was conducted according to the principles of the 
declaration of Helsinki (42).  Approval for the study (Project Number N06/02/017) was 
obtained from the research ethics committee of Stellenbosch University, Faculty of Medicine 
and Health Sciences.  Informed consent was obtained from ASA I-III physical status patients, 
scheduled for elective surgery of expected duration 60 minutes or longer.  Exclusion criteria 
included renal or hepatic dysfunction, myopathies and muscular dystrophies, patients 
receiving any medication known to interact with neuromuscular blocking agents (e.g. 
aminoglycoside antibiotics), patients with potential airway problems and body mass index 
greater than 35. 
 
Anaesthesia 
Patients received a diazepam 10 mg oral premedication two hours pre-operatively.  In the 
operating room, routine monitors (electrocardiography, pulse oximetry, automated non-
invasive blood pressure, capnometry, accelerometry) were prepared and an intravenous 
infusion of Ringer’s Lactate was established after skin infiltration with lignocaine.   
 
The effects of neuromuscular blockade by rocuronium or cisatracurium were measured using 
a nerve stimulator and accelerometry according to the guidelines of Good Clinical Research 
Practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents (10).  
Electrodes of a TOF-GUARD® accelerometric neuromuscular monitor (Organon Teknika, 
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Turnhout, Belgium) were attached to the skin overlying the ulnar nerve at the wrist.  The arm, 
fingers and hand were immobilized on a modified “TOF tube" (17)(16) and the accelerometer 
transducer was taped to the thumb, to which a small preload had been applied using a light 
elastic band. (Figure 1) 
 
 
Figure 1:  TOF-Guard® monitor and modified “TOF tube  
 
After pre-oxygenation via face mask, sufentanil 0.25 µg/kg (actual body weight) was 
administered, followed immediately by an infusion of 0.5 µg/kg/hour using a syringe pump 
(Graseby model 3400).  Calculated blood and effect-site concentrations were monitored using 
pharmacokinetic simulation software (StelSim)♣  employing the pharmacokinetic parameter-
set of Gepts et al. (43).  After approximately 5 minutes, when the simulated sufentanil effect-
site concentrations had reached approximately 0.5 ng/mg, anaesthesia was induced with 
propofol 1-2mg/kg.  Following loss of consciousness, a 50Hz tetanic stimulation of 5 seconds 
                                                 
♣ Authors:  JF Coetzee, P de Kock, University of Stellenbosch 
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duration was applied to the ulnar nerve in order to avoid the “staircase effect" (15).  
Immediately thereafter, monitoring of responses by the Adductor pollicis muscle to twitch 
stimuli (50 mA) using the TOF-GUARD® monitor at one-second intervals was begun.  In 
order to establish comparable control values, the twitch responses were allowed to achieve 
stable values before the monitor was calibrated.  After calibration of the TOF-GUARD® 
monitor, a 3xED95 of either rocuronium (0.9 mg/kg) or cisatracurium (0.15 mg/kg) was 
administered and a stopwatch was started.  Patients’ lungs were ventilated manually via 
facemask until the twitch responses had decreased to 10% of the control value, whereupon 
tracheal intubation was performed.   
 
Anaesthesia was maintained with either desflurane or propofol.  Group DR patients received 
rocuronium during desflurane-sufentanil anaesthesia; Group DC patients received 
cisatracurium during desflurane-sufentanil anaesthesia.  Desflurane end-tidal partial pressures 
were maintained at 4 kPa, while adjusting the sufentanil infusion rates according to patient 
requirements.  Groups PR and PC patients underwent TIVA using propofol and sufentanil.  
Propofol was administered by a separate infusion pump using the regimen of Roberts et 
al.(44)  This comprises infusion rates of 10 mg/kg/h for 10 minutes, followed by 8 mg/kg/h 
for 10 minutes and 6 mg/kg/h thereafter.  Estimated propofol blood concentrations were 
monitored by a separate instance of the pharmacokinetic software StelSim, employing the 
pharmacokinetic parameter set of Marsh et al. (45)  Sufentanil and propofol infusion rates 
were adjusted according to patient requirements for suppression of autonomic responses 
during surgery.  Rocuronium and cisatracurium were administered to Groups PR and PC 
respectively. 
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After intubation, the TOF-GUARD® monitor was set to apply TOF supramaximal stimuli at 
12 second intervals throughout the course of anaesthesia and surgery.  The neuromuscular 
block was allowed to recover spontaneously to a TOFR of 0.9 after which additional 
neuromuscular blocking agent (0.5 x ED95) was administered if judged to be necessary for 
continued surgery.  All data were stored in the memory card of the TOF-GUARD® monitor 
for subsequent transfer to a personal computer and offline analysis. 
 
The sufentanil administration was terminated at the beginning of wound closure and propofol 
administration during skin-closure.   Desflurane administration was terminated after skin-
closure.  If the TOFR was not ≥ 90%, residual neuromuscular blockade was reversed during 
skin closure using neostigmine (0.04 mg/kg) and glycopyrollate (0.08 mg/kg). 
 
Estimation of sample size and patient enrolment 
We regarded a clinically relevant difference in duration of effect to be 15 minutes (SD 12).  
Calculation of the required sample size for four groups required to ensure a power of 0.8 with 
an alpha value of 0.05 revealed that each group should consist of at least 15 subjects.  
Patients were randomly allocated to one of the four designated groups by means of a table of 
random numbers (www.randomization.com).  In order to ensure that the required minimum 
number of patients with complete datasets be enrolled into each group the following 
procedure was followed if reversal of neuromuscular blockade was required before 
spontaneous recovery to TOFR90%:  the patient was disqualified from the study and the next 
study patient was allocated to the disqualified patient’s group.   
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Statistical analysis 
Data were visualized using box-and-whisker plots and tests for group differences were 
performed using one-way analysis of variance (Medcalc Statistical Software (version 
12.3.0.0), Mariakerke, Belgium, http://www.medcalc.org/ ).  If analysis of variance detected a 
significant result then posthoc pairwise group-comparisons were done using the Student-
Newman-Keuls Method.  If the group data did not meet the criteria for equal variances 
(Levene’s test), then nonparametric tests were performed (Kruskal-Wallace) and the posthoc 
test for pairwise comparison of subgroups were done according to Conover. (46)  Confidence 
interval analysis was done using the software package CIA (Trevor Bryant, University of 
Southampton).  An alpha value of 0.05 or less was regarded as indicating statistical 
significance. 
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RESULTS 
Of the 81 patients who were recruited into the study, 63 recovered spontaneously to a TOFR 
of 0.9.  The reason for the dropouts was that the surgery was completed before spontaneous 
neuromuscular recovery was complete, thus necessitating reversal of neuromuscular blockade 
and termination of anaesthesia.  
 
Table 2:  Demographic data 
 DC DR PC PR  
N 15 15 17 16  
Female/Males 13/2 11/4 13/4 13/3  
Age (years) 44.8±8.8 43.8±12.2 47.2±11.4 43.1±15.2 p=0.791 
BMI 25.3±4.9 25.3±4.5 26.24±4.9 23.2±4.1 p=0.311 
 
DC = desflurane-cisatracurium group;  DR = desflurane-rocuronium group;  PC = propofol-
cisatracurium group;  PR = propofol-rocuronium group.  BMI = body mass index 
 
The differences among the groups are not great enough to exclude the possibility that the 
difference is due to random sampling variability.  More females than males were included in 
all the groups. 
 
A typical recording from the TOF-GUARD® is presented in Figure 2.   
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Figure 2: Graphical representation of a recording of a single study patient from the TOF-GUARD® 
x-axis = time, y-axis = twitch height (as a percentage of control), Green lines displayed on the upper 
level are an expansion of the green lines on the lower level, Green lines = twitch response from single 
twitch, Blue lines = twitch response from TOF twitches, Purple dots = TOFR, Red line = temperature 
measured at Adductor pollicis 
 
Accelerometry data of spontaneous recovery times are depicted graphically in Figures 3 to 5 
and results of the one-way ANOVA are depicted in Table 2.  In the box-and-whisker plots, 
the central box represents the values from the lower to upper quartile (25th to 75th percentile).  
The middle line represents the median.  The red square within the square depicts the mean 
value. The vertical line extends from the minimum to the maximum value, excluding outside 
and far out values, which are displayed as separate points.  An outside value is defined as a 
value that is smaller than the lower quartile minus 1.5 times the interquartile range, or larger 
than the upper quartile plus 1.5 times the interquartile range (inner fences).  A far out value is 
defined as a value that is smaller than the lower quartile minus 3 times the interquartile range, 
or larger than the upper quartile plus three times the interquartile range. 
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Figure 3:  Box and whisker plot of times to recovery to T125% 
“Time to 25% control twitch height” = Time from administration to spontaneous recovery of T1 to 25% 
twitch in minutes,  DC = desflurane-cisatracurium group;  DR = desflurane-rocuronium group;  PC = 
propofol-cisatracurium group;  PR = propofol-rocuronium group.   
† = significantly different from PC (p < 0.05). 
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Figure 4:  Box and whisker plot of times to recovery of T125%-75% 
“Time from 25% to 75% twitch height” = Time from administration to spontaneous recovery of T125% - 
75% in minutes, DC = desflurane-cisatracurium group;  DR = desflurane-rocuronium group;  PC = 
propofol-cisatracurium group;  PR = propofol-rocuronium group.   
 
 
  
Stellenbosch University  http://scholar.sun.ac.za
  University of Stellenbosch | RESULTS 41 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Box and whisker plot of times to recovery to TOFR 0.9 
“Time to TOF 90%” = Time from administration to spontaneous recovery to TOFR 0.9 in minutes,  DC 
= desflurane-cisatracurium group;  DR = desflurane-rocuronium group;  PC = propofol-cisatracurium 
group;  PR = propofol-rocuronium group.   
† = significantly different from PC (p < 0.05);  ‡ = significantly different from PR (p < 0.05); * = 
significantly different from PC (p < 0.05). 
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Table 2:  Times to various stages of recovery from neuromuscular blockade after a dosage 
of 3xED95 of cisatracurium or rocuronium during propofol or desflurane anaesthesia 
 n Group
Median 
or 
mean 
25th to 75th 
percentile or 
SD 
P 
(ANOVA) 
Significant 
differences 
between 
groups 
(p<0.05) 
Spontaneous 
Recovery of T1 to 
25% twitch (min) 
17 
16 
14 
13 
PC 
PR 
DC 
DR 
49.2 
49.2 
63.6 
59.2 
9.9 
13.3 
16.8 
18.1 
0.017 
DC 
DC 
PC, PR 
Spontaneous 
Recovery of T1 
from 25% to 75% 
twitch (min) 
12 
12 
13 
11 
PC 
PR 
DC 
DR 
15.3 
19.9 
17.5 
31.1 
16.0 
12.8 
6.2 
22.1 
0.073 
 
Spontaneous 
Recovery TOFR 0.9 
(min) 
17 
16 
15 
15 
PC 
PR 
DC 
DR 
69.9 
89.3 
104.7 
109.6 
64.9 - 72.7 
75.6 - 98.4 
94.2 - 128.2 
88.6 - 141.3 
<0.0001 
PR, DC, DR 
PC, DC, DR 
PC, PR 
PC, PR 
Time to intubation 
(min) 
27 
32 
Roc 
Cis 
0.94 
2.09 
0.58 
0.76 
<0.001 
 
 
n = number of patients;  PC = propofol & cisatracurium; PR = propofol & rocuronium; DC = desflurane 
& cisatracurium; DR = desflurane & rocuronium,  25%-75% = 25th to 75th percentile;  SD = standard 
deviation of the mean;  ANOVA = one-way analysis of variance;  Roc = rocuronium;  Cis = 
cisatracurium 
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The following statistically significant differences in spontaneous recovery indices were found 
between the four groups:  
Mean times for the first TOF twitch response to recover to 25% of control values:  There 
were no statistically significant differences between PC and PR as well as DC and DR.  There 
was a significant difference between PC and DC, but not between PR and DR.   
Mean times for the first TOF twitch response times to recover from T125% to T175%:  No 
statistically significant differences were demonstrated between the four groups.   
Mean times for the first TOF twitch response to recover to 90% of control values:  There 
were no significant differences between the groups, however the data were considered to be 
too sparse to infer a meaningful result and that variable is not further reported or commented 
upon. 
Median times for the TOFR to recover to 90%:  Relations between the times to recovery were 
as follows:  PR > PC;  DC > PC;  DR > PR.   
 
With regard to the spontaneous recovery of the TOFR to 0.9 during propofol-opioid 
anaesthesia (the control groups), the median duration of action of rocuronium was longer than 
that of cisatracurium.  In order to establish whether the relative prolongation by desflurane of 
one NDMR was greater than the relative prolongation of the other and whether there was an 
interaction between the type of NDMR and the type of anaesthetic, two-way analysis of 
variance was performed.  The main effects were the types of anaesthetic and NDMR on 
indices of recovery.  The results are depicted graphically in Figure 6.  The effect of the type 
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of anaesthetic on TOFR0.9 was statistically significant (p < 0.01) whereas the effect of the 
type of relaxant was not (p = 0.063).  There was no interaction (p = 0.26). 
 
 
 
 
 
 
 
 
 
 
Figure 6:  Interaction diagram of TOFR 0.9 
TOF90% = time to recovery to a TOFR of 90% (minutes), Anaesth = type of anaesthetic;  D = 
desflurane;  P = propofol;  C = cisatracurium; R = rocuronium;   
Error bars indicate 95% confidence intervals of the mean values. 
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CONCLUSIONS 
Desflurane significantly prolonged the time to spontaneous recovery after administration of 
NDMR compared to the control. 
 
There was no difference demonstrated between the two muscle relaxants with regard to the 
mean prolongation by desflurane. 
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DISCUSSION 
The purpose of this study was to determine whether desflurane prolongs the duration of 
action of rocuronium and cisatracurium to the same degree.  This study demonstrated that, 
compared to TIVA, desflurane (0.6-0.7 MAC) - opioid anaesthesia prolongs the time to 
spontaneous recovery to T125% and TOFR 0.9 after both cisatracurium (3xED95) and 
rocuronium (3xED95).  We cannot conclude from our data that there was a difference between 
the two muscle relaxants.   
 
Closer examination of the data (Figures 3 to 5) and of the statistical analysis (Table 2) reveals 
that there was wide scatter of the data, including some prominent outliers, so that it is likely 
that the study was underpowered to demonstrate a difference, if it exists.  Table 3 presents the 
95% confidence intervals of the mean prolongation times of the two muscle relaxants.  The 
difference in mean prolongation time is 14.5 minutes (95% confidence interval -11.8 to 40.9), 
which reflects the wide inter-individual variation.  A posthoc sample size calculation reveals 
that in order to detect a real difference, if it exists, with 80% power and alpha 0.05 would 
require 101 subjects per group.  Considering the prolonged mean times to recovery in the 
presence of desflurane (105 and 110 minutes), the mean difference in prolongation of 14.5 
minutes and the presence of wide scatter in the data, it is unlikely that the difference between 
the two NDMR is of clinical importance.  This is in contrast to a study (27) that used 
sevoflurane (2 MAC) and demonstrated that the time to spontaneous recovery to TOFR 0.7 
was significantly prolonged in the cisatracurium group compared to the rocuronium group.  
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To our knowledge, no other study has investigated whether desflurane (in an oxygen and air 
mixture) prolongs the effects of rocuronium and cisatracurium to the same degree or not.   
 
Table 3:  95% confidence intervals of the mean prolongation times of cisatracurium and 
rocuronium 
Comparison 
(Welch’s t-test) 
Mean prolongation  
of time to TOFR90% 
Standard 
deviation 95% CI of difference 
PC vs. DC 41.1 33.6 23.9 to 59.9 
PR vs. DR 26.6 39.2 6.2 to 46.9 
 
PC = propofol & cisatracurium;  DC = desflurane & cisatracurium;  PR = propofol & rocuronium;  DR = 
desflurane & rocuronium, 
 
The effects of desflurane on a single bolus of rocuronium (23) as well as cumulative bolus 
techniques (25)(28)(30) have been explored.  Cumulative bolus techniques have also been 
used to study the effects of desflurane on cisatracurium (26)(29).  These studies have 
investigated the effect of desflurane on the action of either rocuronium or cisatracurium using 
an array of neuromuscular monitoring equipment.  Not one study has demonstrated a 
statistically significant increase in the duration of action of either one of these NDMR in the 
presence of desflurane.  However, this has been attributed to insufficient data regarding the 
effect of desflurane on the time to spontaneous recovery to TOFR 0.75-0.9 after a fixed 
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single dose of NDMR. (26)(25)  In the current study, all patients were allowed to recover 
spontaneously to TOFR 0.9 after receiving equivalent 3xED95 doses of NDMR.   
 
A secondary finding of this study is that during propofol-opioid anaesthesia, the time to 
spontaneous recovery to TOFR 0.9 after rocuronium (3xED95) is greater than that of 
cisatracurium (3xED95).  This is in contrast to a study by Adamus et al. (41) that used 
kinemyography to compare the duration of action of cisatracurium and rocuronium in the 
presence of TIVA and demonstrated no difference between the recovery times of the two 
NDMR.  Their study compared the times from administration of the NDMR (3xED95 doses) 
to T125% as well as the times from T125% to TOFR 0.9.  The time to T125% was identical in 
both groups [rocuronium 52min (SD 12, n=30); cisatracurium 52min (SD 7, n=30)].  In 
comparison, our study also demonstrated identical times to recovery to T125% between the 
two NDMR in the presence of TIVA.  Adamus et al. demonstrated no difference between the 
two NDMR when they compared the times from T125% to TOFR 0.9 [rocuronium 56,7min 
(SD 12.9, n=15); cisatracurium 52.5min (SD 7, n=15)].  In contrast, our study found that the 
median time for interval from administration of rocuronium (in the presence of TIVA) to 
spontaneous recovery to TOFR 0.9 was 19.4 min longer than for the same parameter in the 
cisatracurium group.  The two measurements are not the same and therefore cannot be 
compared. 
 
There are few studies that investigate the duration of action of 3xED95 doses of rocuronium 
or cisatracurium.  As discussed above, Adamus et al. (41), using kinemyography, 
demonstrated the mean time from administration of cisatracurium 0.15mg/kg to T125% in the 
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presence of TIVA was 52min (SD 7, n=30).  In comparison our study demonstrated a mean 
time to T125% in the cisatracurium group administered in the presence of TIVA of 49.2 min.  
Lightall et al. (47), using accelerometry, demonstrated the mean time to T125% after 
cisatracurium 0.15mg/kg was 60min (range 36-76, n=10) in the presence of isoflurane (0.6-
1%) in 50% N2O.  In comparison, our study demonstrated a mean time to T125% in the 
cisatracurium group administered in the presence of desflurane of 63.6 min.  Scultz et al. (38) 
used mechanomyography to study the duration of action of rocuronium in the presence of 
TIVA (in 66%N2O).  They demonstrated a median time from administration of rocuronium 
0,9mg/kg to recovery to T125% was 41min (range 23-72, n=32).  Using kinemyography, 
Adamus et al. (41) demonstrated the mean time from administration of rocuronium 0.9mg/kg 
to T125% was 52min (SD 12, n=30) in the presence of TIVA (no N2O was used).  In 
comparison our study demonstrated a mean time to T125% in the rocuronium group 
administered in the presence of TIVA of 49.2 min.  Majorian et al. (48) used 
mechanomyography to demonstrate the mean time from injection of rocuronium 0.9mg/kg to 
recovery to T125% was 53min (range 35-88, n=9) in the presence of 0.7-1.3% isoflurane (60% 
N2O).  Using accelerometry, Lightall et al. (47) demonstrated the mean time from 
administration of rocuronium 0.9mg/kg T125% in the presence of isoflurane (0.6-1%) in 50% 
N2O was 64min (range 32-85, n=10).  In comparison, our study demonstrated a mean time to 
T125% in the rocuronium group administered in the presence of desflurane of 59.2 min.   
 
It is important to note the wide range of results demonstrated in these studies that investigate 
the duration of action of 3xED95 doses of rocuronium or cisatracurium.  It appears that more 
heterogeneity is demonstrated in the rocuronium groups than the cisatracurium groups.  Very 
wide inter-individual variation was also demonstrated in our study.  The influence of age and 
Stellenbosch University  http://scholar.sun.ac.za
  University of Stellenbosch | DISCUSSION 50 
 
gender on the duration of action of rocuronium has recently been demonstrated for the first 
time. (39)  Our study included a high percentage of female patients and a wide range of ages.  
It appears to be common practice for studies that investigate the duration of action of NDMR 
to include participants from both genders (unmatched) and a wide range of age groups, as this 
is representative of clinical practice.  It would be enlightening to confirm the effect of age 
and gender on duration of action of NDMR.  Future studies should consider including these 
parameters in their criteria to match their groups.  
 
The relevance of this study in clinical practice is the implication that more NDMR will be 
required when using TIVA techniques compared to inhalational techniques.  Nevertheless the 
wide variation in individual patients’ clinical responses to a single fixed dose of NDMR 
emphasizes the need to monitor the effects of the neuromuscular block by means of a 
peripheral nerve stimulator for safe practice. 
 
This study is representative of clinical practice: a 3xED95 dose of NDMR was administered, 
the desflurane was initiated after administration of the NDMR and 0.8 MAC (in O2 and air 
mixture) was targeted.  This is in contrast with studies that used cumulative bolus techniques, 
had minimum mandatory period of volatile agent administration before initiation of the 
neuromuscular blockade, administered greater partial pressures (>1 MAC) and in which the 
presence of nitrous oxide was a confounding factor.  We also paid attention to calibration of 
the TOF-GUARD® monitor and took specific measures to avoid sources of baseline signal 
drift. 
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The question we asked was whether the relative prolongation of one muscle relaxant by the 
volatile was greater than the relative prolongation of the other muscle relaxant.  Thus a cross-
over or matched pair design would have been ideal.  A 3xED95 dose is large; therefore the 
duration of muscle relaxation was prolonged.  This resulted in 18 recruited patients dropping 
out of the study and this may have biased the results towards patients who had a quicker 
recovery.  A smaller dose may have demonstrated a significant difference in the prolongation 
of neuromuscular block between the two NDMR.  Thus to elucidate the prolongation of 
desflurane on cisatracurium and rocuronium further, the study should be expanded to include 
the effect after administration of a 1 and 2x ED95 doses of the muscle relaxants.  
 
The current study was unable to demonstrate an interaction between the type of NDMR and 
the degree of potentiation on its duration of action by the volatile agent.  Thus, any 
differences in the potentiation of duration of action of the potent and less potent NDMR by 
desflurane are unlikely to be of clinical importance.   
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ADDENDUM 
Table A1:  Studies investigating the effects of modern volatile anaesthetic agents on modern neuromuscular blockers 
 
  
Study NMB Dosage Volatile/ 
IVdrug 
N2O 
Exposure 
to volatile 
before 
NDMR 
Measuring 
technique 
Results 
Potency Onset time Duration of recovery 
Rupp et 
al.1985 
 
 
 
 
 
 
 
(Rupp et 
al.1983) 
Atracuri
um 
Randomly 
allocated to 
receive single 
bolus of 50, 60, 
70, 80, 90 or 
100μg/kg to 
construct a dose-
response curve 
1.25 MAC:  
Halothane 
Enflurane 
(included 0.6 
MAC 
contribution 
from N2O)  
 
Results 
compared with 
data from a 
previous study 
using identical 
techniques by 
same lead 
author: 
1.25 MAC: 
Isoflurane; 
Fentanyl 7-
10μg/kg bolus 
with induction 
60% 30 min Mechano-
myography 
 
Twitch 
height 
ED50: 
Halothane:  77μg/kg 
Enflurane:   70μg/kg* 
Isoflurane:  68μgkgl* 
Fentanyl:    83μg/kg 
(* Different from Fentanyl 
P<0.05) 
 
 
Thus: 
- No difference Halothane vs. 
Enflurane  
- Enflurane and Isoflurane 
significantly increased the 
potency of atracurium vs 
Fentanyl 
 
No difference Duration50: 
Halothane:  25.5 min 
Enflurane:   34.2 min* 
Isoflurane:  25.5 min 
Fentanyl:    21.6 min 
(* Different from Fentanyl P<0.05) 
 
 
Thus: 
- No difference Halothane vs Enflurane 
- 33% increase by Enflurane vs Fentanyl 
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Table A1 (continued):   
Study NMB Dosage Volatile/ 
IVdrug 
N2O 
Exposure 
to volatile 
before 
NDMR 
Measuring 
technique 
Results 
Potency Onset time Duration of recovery 
Wright et al. 
1995 
Vecuro
nium 
Potentiation 
studies:  Dose-
response 
 
Onset and 
duration studies: 
100μg/kg 
 
50% of participant 
involved in potentiation 
studies and 50% 
involved in onset and 
duration studies 
 
All participants crossover 
6 days apart 
 
 
1.25 MAC:  
Desflurane 
Isoflurane  
70% 
 
 
 
Poten-
tiation 
studies: 
N20 
added 
after 
90% 
twitch 
suppress
ion 
achieved 
by 
NDMR 
60 min Mechano-
myography 
 
Twitch 
tension 
ED50: 
Desflurane:  8.7μg/kg 
Isoflurane:  10.7μg/kg 
 
Vecuronium infusion 
requirements to maintain same  
twitch height: 
Desflurane:  0.65μg/kg/min 
Isoflurane:   0.79μ/kg/min 
 
 
Thus: 
Desflurane 20% > Isoflurane 
Time to maximum 
blockade: 
Des: 62 sec 
Iso:  73 sec 
(P< 0.05)  
 
 
 
 
Thus: 
Desflurane 
significantly faster 
than Isoflurane 
Time (min) until:    Des    Iso 
25% recovery         69       55 
90% recovery       135     110    (P <0.01) 
T1 25%-75%           41       34    (P<0.05) 
 
 
 
 
 
 
Thus: 
Desflurane prolonged recovery vs 
Isoflurane  
Kumar et al. 
1996 
Rocuro
nium 
Potentiation 
studies: 
Randomly 
allocated to 
receive a single 
bolus of 
75, 150, 225, or 
300μg/kg 
 
Onset and 
duration studies: 
0.6mg/kg 
1.0 MAC:  
Desflurane 
Isoflurane  
66% 10 min Mechano-
myography 
 
Twitch 
height 
 
TOFR 
ED50: 
Desflurane:  138μg/kg 
Isoflurane:   126μg/kg 
 
 
 
 
 
Thus: 
- No difference Desflurane vs 
Isoflurane 
Time to maximum 
blockade 
Des: 1.0 min 
Iso:  1.1 min 
(P=0.09)  
 
 
Thus: 
- Desflurane non-
significantly faster 
than Isoflurane 
Time (min) until:   Des       Iso 
25% recovery         36         31 
90% recovery         54         45   (P>0.1) 
TOFR 0.7               66         52   (P>0.05) 
T1 25%-75%          14         10   (P>0.05) 
 
 
 
Thus: 
- Non-significant prologation of recovery 
times with Desflurane vs Isoflurane 
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Table A1 (continued): 
Study NMB Dosage Volatile/ 
IVdrug 
N2O 
Exposure 
to volatile 
before 
NDMR 
Measuring 
technique 
Results 
Potency Onset time Duration of recovery 
Lowry et al. 
1998 
Rocuro
nium 
Potency studies: 
Randomly 
allocated to 
receive a single 
bolus of 
75, 150, 225, or 
300μg/kg 
 
Onset and 
duration studies: 
0.6mg/kg 
 
1.5 MAC:  
Sevoflurane 
Isoflurane 
Propofol 6-
12mg/kg/hr 
66% 10 min Mechano-
myogr 
 
Twitch 
height 
 
TOFR 
 
ED50: 
Sevofllurane:  142μg/kg* 
Isoflurane:      165μg/kg 
Propofol:        183μg/kg 
(* Different from Propofol 
P<0.05) 
 
 
 
 
Thus: 
- Significant difference with 
Sevoflurane vs Propofol 
Time to maximum 
blockade 
Sevo: 0.96 min 
Iso:     0.9 min 
Prop:  1.02 min 
 
 
 
Thus: 
- No difference  
 
Time (min) until:  Sevo  Iso  Prop 
25% recovery         45     35     35 
90% recovery         83     56     55 
TOFR 0.8              103*    69    62 
T1 25%-75%           26*    12    14 
(* P<0.01 for sevoflurane vs isoflurane and 
propofol)) 
 
 
Thus: 
- Sevoflurane prolonged recovery  to 
TOFR 0.8 and recovery from 25% twitch 
height to 75% twitch height vs Isoflurane 
and Propofol 
Wulf et al. 
1998 
Rocuro
nium 
Cumulative bolus 1.5 MAC:  
Desflurane 
Sevoflurane 
Isoflurane 
TIVA with 
Propofol/Fent
anyl (doses 
not specified) 
70% Not 
specified 
Accellero-
metry 
 
Twitch 
height  
 
TOFR  
ED50: 
Desfllurane:    95μg/kg* 
Isoflurane:     130μg/kg 
Sevoflurane: 1 20μg/kg* 
TIVA:              150μg/kg 
(* P<0.05) 
 
Thus: 
- Desflurane and Sevoflurane 
reduced the ED50 vs propofol 
TIVA 
Not studied Time (min) until:  Des    Iso     Sevo   Prop   
25% recovery     13.2    13.9   15.5    13.9 
TOFR 0.7            26.9   26.3    31.0   27.5 
T1 25%-75%      12.7    10.7    11.4   11.3 
 
 
 
 
Thus: 
- No prolongation by the volatiles 
Wulf et al. 
1998 
Cisatac
urium 
Cumulative bolus 1.5 MAC:  
Desflurane 
Sevoflurane 
Isoflurane 
TIVA with 
Propofol/Fent
anyl (doses 
not specified) 
 
70% Not 
specified 
Accellero-
metry 
 
Twitch 
height 
 
TOFR 
ED50: 
Desfllurane:  15μg/kg* 
Isoflurane:     15μg/kg* 
Sevoflurane: 15μg/kg* 
TIVA:            21μg/kg 
(* P<0.05) 
 
Thus: 
- Volatiles reduced the ED50 vs 
propofol 
 
Not studied Time (min) until:  Des   Iso   Sevo   Prop   
25% recovery        19    20    19      16 
TOFR 0.7               43   41     44      35   
T1 25%-75%         18    14     19     12 
 
 
 
Thus: 
- No prolongation by the volatiles 
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Table A1 (continued): 
Study NMB Dosage Volatile/ 
IVdrug 
N2O 
Exposure 
to volatile 
before 
NDMR 
Measuring 
technique 
Results 
Potency Onset time Duration of recovery 
Amin et al. 
2009 
Cisatrac
urium 
 
Rocuro
nium 
Cumulative bolus 2 MAC: 
Sevoflurane 
Propofol 
100μg/kg/min 
50% 10-15 
min 
Accellero-
metry 
 
Twitch 
height  
 
TOFR 
ED50: 
Roc+Sevo:    124μg/kg 
Cis + Sevo:     17μg/kg 
Roc + Prop:  150μg/kg* 
Cis + Prop:     23μg/kg# 
(* P<0.01 compared with Roc + 
Sevo group) 
(# P<0.01 compared to Cis + 
Sevo group) 
 
 
Thus: 
- Sevoflurane reduced ED50 vs 
propofol by 20% in both NMB 
Not studied Time (min) until:   RS    CS     RP   CP  
25% recovery       18     19      15    16 
TOFR 0.7             36*    44*#  29     34# 
T1 25%-75%        13*    18*#    9     14# 
(* P <0.05 same NDMR< different 
anaesthetic) 
(# P<0.05 same anaesthetic, different 
NDMR) 
 
 
 
Thus: 
- Prolonged recovery 25%-75% & TOFR 
0.7 of Cisatracurium > Rocuronium 
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Table A1 (continued): 
Study NMB Dosage Volatile/ 
IVdrug 
N2O 
Exposure 
to volatile 
before 
NDMR 
Measuring 
technique 
Results 
Potency Onset time Duration of recovery 
Bock et al. 
2000 
Rocuro
nium 
Randomly 
allocated to 
receive single 
bolus of 0.1, 0.15 
or 0.2mg/kg to 
construct a dose-
response curve  
 
After maximal 
depression 
recorded, a 
supplementary 
dose of 
rocuronium given 
so that all subjects 
received 
cumulative dose of 
0.3mg/kg 
 
After recovery of 
T1 to 5% of 
control, 
rocuronium 
infusion started 
and adjusted to 
maintain T1 5-10% 
twitch height. 
 
1.25 MAC:  
Desflurane 
Sevoflurane 
Isoflurane 
Propofol (4-
6mg/kg/hr) 
60% 40 min Electro-
myography 
 
Twitch 
height  
 
TOFR 
ED50 
Propofol:          169μg/kg 
Isoflurane:        126μg/kg 
Desflurane:       136μg/kg 
Sevoflurane:    121μg/kg 
 
ED90 
Propofol:          358μg/kg* 
Isoflurane:        288μg/kg 
Desflurane:        250μ/kg 
Sevoflurane:     289μg/kg 
(*P<0.05) 
 
 
Thus: 
- No difference in ED50 
- Significant difference in ED90 
for propofol compared to 
volatiles 
- Showed leftward shift of dose 
response curve for volatiles vs 
propofol 
- And a 30-40% decrease in the 
infusion rate of rocuronium 
during volatile anaesthesia 
compared to propofol   
 
Not studied Time (min)           Prop  Iso   Des  Sevo 
TOFR 0.25-0.7      22     27    26     28 
 
 
 
 
 
 
 
 
 
 
 
 
Thus: 
- No prolongation with volatiles 
 
 
 
 
Recovery index defined as TOFR 0.25-
0.70 
 
Compared to all other studies (and the 
GCPR guidelines) that defined Recovery 
index as T1 25%-75% 
 
 
  
Stellenbosch University  http://scholar.sun.ac.za
  University of Stellenbosch | ADDENDUM 57 
 
Table A1 (continued): 
Study NMB Dosage Volatile/ 
IVdrug 
N2O 
Exposure 
to volatile 
before 
NDMR 
Measuring 
technique 
Results 
Potency Onset time Duration of recovery 
Hemmerling 
et al. 
2001 
Cisatrac
urium 
Closed-loop 
control to 10% 
twitch height 
 
 
 
 
 
Infusion rate of 
cisatracurium used to 
estimate the Effective 
Therapeutic index (μg x 
m2BSA x min-1) 
 
1.3 MAC:  
Desflurane 
Sevoflurane 
Isoflurane 
Propofol (6-
8mg/kg/hr) 
None Volatile 
started 
after 
NDMR – 
induced 
T1% < 
5%i 
 
Only study to 
start volatile 
after 
administration 
of NDMR 
 
Electro-
myography 
 
Twitch 
height 
 
Effective Therapeutic index 
Propofol:         61.7μg.m-2.min-1 * 
Desflurane:     23.8 μg.m-2.min-1# 
(*P<0.002 for Propofol vs all 
volatiles) 
(#P<0.02 for Des vs Prop, Sevo, 
Iso) 
 
 
Thus: 
- Volatiles significantly 
decreased the infusion rate 
required 
- Desflurane significantly 
increased the potency of 
cisatracurium compared to 
other volatiles studied 
Not studied Reduced cumulated dose requirements 
compared to Propofol:  
Desflurane      60% 
Sevoflurane    42% 
Isoflurane       41%  
(p<0.002 for Propofol vs all volatiles) 
(p<0.02 for Des vs prop, sevo, iso) 
 
Stout et al. 
2006 
Rocuro
nium 
Single bolus 
0.6mg/kg) then 
infusion (10-12 
μg/kg/min) to 
maintain T1 at 
10% 
Desflurane  
(ETDes 3-8%) 
Propofol  
(100-
150μg/kg) 
50% Not 
specified 
Electro-
myography 
 
Twitch 
height 
 
Rocuronium infusion rate 67% 
less with Desflurane than 
Propofol 
Time to T1 10% 
Des:   198 sec 
Prop:  118 sec 
(p = 0.034) 
 
 
Thus: 
- Onset was 
prolonged by 
Desflurane. 
 
Time (min) until:     Des       Prop 
T1 25%                   19          16 
T1 50%                   27          21 
T1 75%                   44          28 
(P>0.05) 
T1 90%                   68          46 
(number too small for statistical 
comparison) 
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